Schizophrenia Research
Volume 56, Issue 1 , Pages 1-10 , 1 July 2002

Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials

  • Arja Tuunainen

      Affiliations

    • Department of Psychiatry, University of Helsinki, EU-PSI Project, Hesperia Hospital, P.O. Box 590, FIN-00029 Huch, Helsinki, Finland
    • Corresponding Author InformationCorresponding author. +358-9-471-63776; fax: +358-9-471-3-775
    • ,
  • Kristian Wahlbeck

      Affiliations

    • Department of Psychiatry, University of Helsinki, Lappviksvägen, P.O. Box 320, FIN-00029 Huch, Helsinki, Finland
    • ,
  • Simon Gilbody

      Affiliations

    • NHS Centre for Reviews & Dissemination, University of York, Y01 5DD, York, UK

Received 7 April 2000 ,Revised 26 February 2001 ,Accepted 5 March 2001.

References 

  1. Altman DG, Bland JM. Detecting skewness from summary information. Br. Med. J. 1996;313:1200
  2. Anand, R., Alphs, L., Azorin, J.M., Remington, G., Péré, J.-J., Bourdeix, I., 1998. Superior efficacy of clozapine in chronic, severe schizophrenia: comparison with risperidone. In: Highlights. Treatment-resistant schizophrenia and beyond. Current concepts and future prospects. London, 8–9 July.
  3. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch. Gen. Psychiatry. 1982;39:784–788
  4. Beasley, C.M. Jr., Beuzen, J.-N., Birkett, M.A., Kiesler, G.M., Tollefson, G.D., Wood, A.J., 1999. Olanzapine versus clozapine: an international double-blind study of the treatment of resistant schizophrenia. Presented at the American Psychiatric Association 152nd Annual Meeting in Washington, DC, 15–20 May.
  5. Beuzen, J.N., Birkett, M.A., Kiesler, G.M., Wood, A.J., 1998. Olanzapine versus clozapine: a double-blind international study in the treatment of resistant schizophrenic patients. Presented at the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress in Glasgow, 12–16 July.
  6. Bondolfi, G., Baumann, P., Patris, M., May, J.P., Billeter, U., Dufour, H., 1995a. A randomized double-blind trial of risperidone versus clozapine for treatment resistant chronic schizophrenia. Presented at the 148th American Psychiatric Association Annual Meeting in Miami, FL, 20–25 May.
  7. Bondolfi G, Baumann P, Patris M, May JP, Billeter U, Dufour H. A randomized double-blind trial of risperidone versus clozapine for treatment resistant chronic schizophrenia. Eur. Neuropsychopharmacol. 1995;5:349
  8. Bondolfi G, Baumann P, Dufour H. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. Eur. Neuropsychopharmacol. 1996;6:S2-21-S2-25
  9. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am. J. Psychiatry. 1998;155:499–504
  10. Breier AF, Malhotra AK, Su T-P, Pinals DA, Elman I, Adler CM, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine responses. Am. J. Psychiatry. 1999;156:294–298
  11. Cheine MV, Wahlbeck K, Tuisku K, Joffe G. Risperidone versus clozapine in the treatment of neuroleptic-refractory/intolerant schizophrenia patients: a single-blind randomized trial. Preliminary report of an on-going study. Nord. J. Psychiatry. 1997;51:99
  12. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, et al. The risks and benefits of clozapine versus chlorpromazine. J. Clin. Psychopharmacol. 1987;7:377–384
  13. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effects. Br. Med. J. 1995;310:452–454
  14. Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am. J. Psychiatry. 1996;153:417–419
  15. Dickersin K. The existence of publication bias and risk factors for its occurrence. J. Am. Med. Assoc. 1990;263:1385–1389
  16. Egger M, Smith GD. Bias in location and selection of studies. Br. Med. J. 1998;316:61–66
  17. Fleischhacker WW. Clozapine: a comparison with other novel antipsychotics. J. Clin. Psychiatry. 1999;60(Suppl.12):12–34
  18. Guy, W., 1976. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Publication no 76–338. National Institute of Mental Health, Rockville, MD, pp. 218–222.
  19. Heinrich, K., 1992. Risperidone versus clozapine in acute schizophrenia. Presented at the 1st International Risperidone Investigators’ Meeting, Paris, 9–16 March.
  20. Heinrich, K., Klieser, E., Lehmann, E., Kinzler, E., 1991. Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia. In: Kane, J.M. (Ed.), Risperidone — major progress in antipsychotic treatment. Proceedings of a Satellite Symposium at the 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum, Kyoto, pp. 37–39.
  21. Heinrich K, Klieser E, Lehmann E, Kinzler E. Experimental comparison of the efficacy and compatibility of clozapine and risperidone in acute schizophrenia. Clin. Neuropharmacol. 1992;15(Suppl. 12):375B
  22. Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomized trial. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 1994;18:129–137
  23. Kane JM. Treament-resistant schizophrenic patients. J. Clin. Psychiatry. 1996;57:35–40
  24. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988;45:789–796
  25. Kay SR. Positive and negative symptoms in schizophrenia. Assessment and research. New York: Brunner-Mazel; 1991;
  26. Kerwin RW. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br. J. Psychiatry. 1994;164:141–148
  27. Kerwin R, Taylor D. New antipsychotics. A review of their current status and clinical potential. CNS Drugs. 1996;6:71–82
  28. Klieser, E., Kinzler, E., 1991. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomized trial. Clinical Research Report on R64766 Ris-FRG-9005.
  29. Klieser E, Rappard F. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with acute exacerbations of schizophrenia. Eur. Psychiatry. 1994;9(Suppl 1):154S
  30. Klieser E, Strauss WH. Quasi-experimental comparison of the efficacy of classical and atypical neuroleptics in acute schizophrenia with respect to their cognitive and emotional side effects. Pharmacopsychiatry. 1993;26:168
  31. Klieser, E., Strauss, W.H., Burtscheid, W., 1986. Double-blind comparative study of haloperidol, remoxipride and clozapine in schizophrenia. Presented at the 15th Collegium Internationale Neuro-Psychopharmacologicum Congress, San Juan, Puerto Rico, 14–17 December.
  32. Klieser E, Strauss WH, Lemmer W. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta Psych. Scand. 1994;89(Suppl 380):68–73
  33. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 1995;15(Suppl 1):45S–51S
  34. Klieser E, Lehmann E, Heinrich K. Risperidone in comparison with various treatments of schizophrenia. In:  Kane JM,  Möller H-J,  Awouters F editor. Medicine Psychiatry, Vol. 3. Serotonin in Antipsychotic Treatment: Mechanisms and Clinical Practice. New York: Marcel Dekker; 1996;p. 331–343
  35. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 1999;35:51–68
  36. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Nat. Cancer Inst. 1959;22:719–748
  37. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics Part I: pharmacology, pharmacokinetics, and efficacy. Ann. Pharmacother. 1999;33:73–85
  38. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann. Intern. Med. 1997;126:712–720
  39. Meyer-Lindenberg A, Gruppe H, Bauer U, Lis S, Krieger S, Gallhofer B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results form a double-blind study. Pharmacopsychiatry. 1997;30:35–42
  40. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998;352:609–613
  41. Mulrow, C.D., Oxman, A.D. (Eds.), 1997. Cochrane Collaboration Handbook. The Cochrane Library, Issue 4. Update Software, Oxford, Updated September 1997.
  42. Oliemeulen EAP, van Hoof JJM, Jogems-Kosterman BJM, Hulstijn W, Tuynman-Qua HG. Is olanzapine a substitute for clozapine? The effects on psychomotor performance. Schizophr. Res. 2000;41:187
  43. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962;10:799–812
  44. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomised controlled trials. N. Engl. J. Med. 1987;316:450–455
  45. Schooler NR. New antipsychotic medications: strategies for evaluation and selected findings. Schizophr. Res. 1997;27:249–259
  46. Su T-P, Malhotra AK, Hadd K, Breier A, Pickar D. D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients. Arch. Gen. Psychiatry. 1997;54:972–973
  47. Tuunainen, A., Wahlbeck, K. and Gilbody, S.M., 2000. Newer atypical antipsychotic medication versus clozapine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 3. Update Software: Oxford.
  48. Waddington JL, Scully PJ, O'Callaghan E. The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophr. Res. 1997;28:207–222
  49. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am. J. Psychiatry. 1999;156:990–999
  50. Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimón R. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 2000;24:911–922

PII: S0920-9964(01)00212-2

doi: 10.1016/S0920-9964(01)00212-2

Schizophrenia Research
Volume 56, Issue 1 , Pages 1-10 , 1 July 2002

Article Tools

* Image Usage & Resolution